Orchid Pharma Limited (ORCHPHARMA) - Net Assets

Latest as of March 2026: Rs12.88 Billion INR ≈ $139.27 Million USD

Based on the latest financial reports, Orchid Pharma Limited (ORCHPHARMA) has net assets worth Rs12.88 Billion INR (≈ $139.27 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs19.11 Billion ≈ $206.66 Million USD) and total liabilities (Rs6.23 Billion ≈ $67.39 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check tangible net worth ratio of Orchid Pharma Limited to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric	Value
Current Net Assets	Rs12.88 Billion
% of Total Assets	67.39%
Annual Growth Rate	5.34%
5-Year Change	98.92%
10-Year Change	N/A
Growth Volatility	244.72

Orchid Pharma Limited - Net Assets Trend (2004–2026)

This chart illustrates how Orchid Pharma Limited's net assets have evolved over time, based on quarterly financial data. See ORCHPHARMA defensive asset coverage days to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for Orchid Pharma Limited (2004–2026)

The table below shows the annual net assets of Orchid Pharma Limited from 2004 to 2026. For live valuation and market cap data, see Orchid Pharma Limited market capitalisation.

Year	Net Assets	Change
2026-03-31	Rs12.88 Billion ≈ $139.27 Million	+1.62%
2025-03-31	Rs12.67 Billion ≈ $137.05 Million	+8.36%
2024-03-31	Rs11.69 Billion ≈ $126.47 Million	+69.82%
2023-03-31	Rs6.89 Billion ≈ $74.47 Million	+6.37%
2022-03-31	Rs6.47 Billion ≈ $70.01 Million	-0.85%
2021-03-31	Rs6.53 Billion ≈ $70.61 Million	-14.76%
2020-03-31	Rs7.66 Billion ≈ $82.84 Million	+208.80%
2019-03-31	Rs-7.04 Billion ≈ $-76.14 Million	+11.08%
2018-03-31	Rs-7.92 Billion ≈ $-85.63 Million	-69.63%
2017-03-31	Rs-4.67 Billion ≈ $-50.48 Million	-1051.67%
2016-03-31	Rs490.45 Million ≈ $5.30 Million	-85.11%
2015-03-31	Rs3.29 Billion ≈ $35.62 Million	-13.46%
2013-03-31	Rs3.81 Billion ≈ $41.16 Million	-67.84%
2012-03-31	Rs11.83 Billion ≈ $127.98 Million	+10.47%
2011-03-31	Rs10.71 Billion ≈ $115.84 Million	+14.24%
2010-03-31	Rs9.38 Billion ≈ $101.40 Million	+47.94%
2009-03-31	Rs6.34 Billion ≈ $68.54 Million	-4.69%
2008-03-31	Rs6.65 Billion ≈ $71.92 Million	+37.08%
2007-03-31	Rs4.85 Billion ≈ $52.46 Million	-37.45%
2006-03-31	Rs7.76 Billion ≈ $83.88 Million	+68.32%
2005-03-31	Rs4.61 Billion ≈ $49.83 Million	+12.30%
2004-03-31	Rs4.10 Billion ≈ $44.38 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Orchid Pharma Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 0.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (March 2026)

Component	Amount	Percentage
Common Stock	Rs507.19 Million	3.94%
Other Components	Rs12.37 Billion	96.06%
Total Equity	Rs12.88 Billion	100.00%

Orchid Pharma Limited Competitors by Market Cap

The table below lists competitors of Orchid Pharma Limited ranked by their market capitalization.

Company	Market Cap
BlackRock MIT II NYSE:BLE	$503.04 Million
Dingli Communications Corp Ltd SHE:300050	$503.08 Million
Bright Oceans Inter Telecom Corp SHG:600289	$503.27 Million
Guangdong Hybribio Biotech Co Ltd SHE:300639	$503.29 Million
Gulf Oil Lubricants India Limited NSE:GULFOILLUB	$502.94 Million
Shenzhen Longtech Smart Control Co. Ltd. SHE:300916	$502.90 Million
Ambassador Hotel Ltd TW:2704	$502.86 Million
Beijing Jingyeda Technology Co Ltd SHE:003005	$502.81 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Orchid Pharma Limited's equity between the two most recent reporting periods.

Equity Growth Insights

From 2025 to 2026, total equity changed from 12,672,854,000 to 12,877,850,000, a change of 204,996,000 (1.6%).
Net income of 205,470,000 contributed positively to equity growth.
Other comprehensive income decreased equity by 18,890,966,000.
Other factors increased equity by 18,890,492,000.

Equity Change Factors (2025 to 2026)

Factor	Impact	Contribution
Net Income	Rs205.47 Million	+1.6%
Other Comprehensive Income	Rs-18.89 Billion	-146.69%
Other Changes	Rs18.89 Billion	+146.69%
Total Change	Rs-	1.62%

Book Value vs Market Value Analysis

This analysis compares Orchid Pharma Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 3.61x
The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
The price-to-book ratio has decreased from 11.49x to 3.61x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2004-03-31	Rs79.81	Rs917.10	x
2005-03-31	Rs89.63	Rs917.10	x
2006-03-31	Rs127.60	Rs917.10	x
2007-03-31	Rs66.39	Rs917.10	x
2008-03-31	Rs67.94	Rs917.10	x
2009-03-31	Rs70.64	Rs917.10	x
2010-03-31	Rs105.60	Rs917.10	x
2011-03-31	Rs125.42	Rs917.10	x
2012-03-31	Rs165.58	Rs917.10	x
2013-03-31	Rs53.93	Rs917.10	x
2015-03-31	Rs42.32	Rs917.10	x
2016-03-31	Rs5.64	Rs917.10	x
2017-03-31	Rs-52.46	Rs917.10	x
2018-03-31	Rs-89.00	Rs917.10	x
2019-03-31	Rs-79.12	Rs917.10	x
2020-03-31	Rs86.23	Rs917.10	x
2021-03-31	Rs159.96	Rs917.10	x
2022-03-31	Rs158.61	Rs917.10	x
2023-03-31	Rs168.72	Rs917.10	x
2024-03-31	Rs241.80	Rs917.10	x
2025-03-31	Rs249.88	Rs917.10	x
2026-03-31	Rs253.84	Rs917.10	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Orchid Pharma Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 1.60%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 2.53%
• Asset Turnover: 0.42x
• Equity Multiplier: 1.48x
Recent ROE (1.60%) is above the historical average (-27.54%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2004	6.10%	3.74%	0.47x	3.48x	Rs-159.96 Million
2005	4.79%	3.06%	0.40x	3.93x	Rs-239.87 Million
2006	7.39%	6.12%	0.43x	2.80x	Rs-202.59 Million
2007	16.19%	8.15%	0.33x	5.96x	Rs300.39 Million
2008	26.37%	13.48%	0.37x	5.24x	Rs1.09 Billion
2009	-7.73%	-3.78%	0.31x	6.68x	Rs-1.12 Billion
2010	36.18%	25.25%	0.36x	4.02x	Rs2.45 Billion
2011	14.61%	8.77%	0.44x	3.81x	Rs492.62 Million
2012	8.26%	5.44%	0.45x	3.38x	Rs-205.76 Million
2013	-97.90%	-28.65%	0.28x	12.24x	Rs-4.10 Billion
2015	-39.80%	-11.26%	0.29x	12.33x	Rs-1.64 Billion
2016	-569.10%	-32.47%	0.22x	78.75x	Rs-2.84 Billion
2017	0.00%	-62.20%	0.24x	0.00x	Rs-4.49 Billion
2018	0.00%	-51.65%	0.22x	0.00x	Rs-2.74 Billion
2019	0.00%	11.57%	0.19x	0.00x	Rs1.40 Billion
2020	-17.11%	-27.09%	0.33x	1.91x	Rs-2.08 Billion
2021	-17.85%	-25.89%	0.36x	1.89x	Rs-1.82 Billion
2022	-0.30%	-0.35%	0.50x	1.72x	Rs-666.89 Million
2023	6.73%	6.96%	0.54x	1.78x	Rs-225.47 Million
2024	7.88%	11.25%	0.53x	1.33x	Rs-247.80 Million
2025	7.86%	10.81%	0.55x	1.33x	Rs-270.72 Million
2026	1.60%	2.53%	0.42x	1.48x	Rs-1.08 Billion

Industry Comparison

This section compares Orchid Pharma Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $28,467,590,098
Average return on equity (ROE) among peers: 15.37%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Orchid Pharma Limited (ORCHPHARMA)	Rs12.88 Billion	6.10%	0.48x	$503.04 Million
Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS)	$83.97 Million	10.78%	0.83x	$23.87 Million
Aarti Drugs Limited (AARTIDRUGS)	$4.11 Billion	19.62%	1.87x	$366.89 Million
Aarti Pharmalabs Limited (AARTIPHARM)	$2.31 Million	-8.08%	0.08x	$628.53 Million
Abbott India Limited (ABBOTINDIA)	$6.47 Billion	22.37%	0.40x	$6.04 Billion
Ajanta Pharma Limited (AJANTPHARM)	$20.41 Billion	22.96%	0.20x	$4.23 Billion
Akums Drugs and Pharmaceutical (AKUMS)	$7.20 Billion	-0.56%	3.88x	$1.03 Billion
Alkem Laboratories Limited (ALKEM)	$124.34 Billion	17.42%	0.42x	$6.85 Billion
Amrutanjan Health Care Limited (AMRUTANJAN)	$1.29 Billion	15.52%	0.29x	$174.31 Million
Alembic Pharmaceuticals Limited (APLLTD)	$3.95 Billion	32.95%	1.66x	$1.58 Billion
Aurobindo Pharma Limited (AUROPHARMA)	$116.82 Billion	20.74%	0.81x	$9.16 Billion

About Orchid Pharma Limited

NSE:ORCHPHARMA India Drug Manufacturers - Specialty & Generic

Market Cap

$503.04 Million

Rs46.51 Billion INR

Market Cap Rank

#12362 Global

#593 in India

Share Price

Rs917.10

Change (1 day)

+8.41%

52-Week Range

Rs482.45 - Rs917.10

All Time High

Rs2527.90